Full text is available at the source.
Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study
Continuous glucose monitoring measures linked to fatty liver disease in adults with type 1 diabetes using liver stiffness testing
AI simplified
Abstract
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is 35.1% among individuals with type 1 diabetes (T1D).
- Time above range 180-250 mg/dl (TAR1) is significantly associated with increased liver fat as measured by controlled attenuation parameter (CAP).
- The association between TAR1 and CAP remains significant after accounting for age, sex, body mass index (BMI), HbA1c, and total daily insulin dose.
- Older age, male sex, BMI, and total daily insulin dose are also independently associated with higher CAP values.
- BMI was identified as the most important factor influencing CAP, followed by age, total daily insulin dose, and TAR1.
AI simplified